The biotechnology company, which sees itself as "pretty conservative," recently put out an ambitious long-term revenue ...

Shares in Amgen fell by double digits Tuesday on results for the company’s MariTide shot, which is viewed as a potential ...

The deal suggests Roche sees substantial promise in Poseida’s technology, as the offer is 215% above the biotech’s closing ...

BridgeBio shares climbed by nearly 25% Monday on news its drug for a cardiac form of transthyretin amyloidosis was approved ...

Reduced Weight Regain: CCT-217 shows promise in preventing weight regain commonly observed after discontinuing incretin ...

Evotec appears to have rebuffed Halozyme’s $2.1 billion acquisition attempt. Elsewhere, Argenx has another blockbuster target ...

Revuforj is the first so-called menin inhibitor cleared in the U.S., securing FDA approval for use in adults and certain ...

Negative results from a Huntington’s trial add to a calamitous year for Sage, which last month decided to overhaul its ...

Patsnap, a global leader in innovation and pharma intelligence, announced the launch of Hiro Life Sciences (Hiro LS), a groundbreaking AI assistant poised to redefine biopharmaceutical research and ...

The brain drug developer is letting go of around 41 of its 238 employees, in a move the company says will help “align resources” with its strategic priorities.

Despite plans to shutter 1,200 stores, the company’s chief clinical trials officer said the pharmacy giant remains committed ...

Sarepta Therapeutics has turned to dealmaking to restock a drug pipeline analysts worried was growing thin, announcing Tuesday a deal with Arrowhead Pharmaceuticals that will give it four ...